Publication | Closed Access

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

Medicinal ChemistrySignaling PathwayFms-like Tyrosine Kinase-3MedicineReceptor Tyrosine KinaseRational Drug DesignClinical Candidate Sb1317/tg02Structure-based DesignAnti-cancer AgentSystems BiologyPharmacologyCell SignalingNovel TherapyDrug DiscoveryJak-stat Signaling Pathway